jeudi 14 mai 2020

Onco Actu du 14 mai 2020


1. BIOLOGIE



Cancer cells deactivate their ‘Velcro’ to go on the attack [UC Louvain]











4.16 DÉP., DIAG. & PRONO. - PANCRÉAS



Diabetes type 3c is confirmed as an early manifestation of pancreatic cancer [CNIO]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



New treatment extends lives of people with most common type of liver cancer [UCLA]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info [Xconomy]











Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma [BMS]











Bristol Myers, bluebird to resubmit cancer therapy filing as FDA declines review [Reuters]











Bristol-Myers CVR Sinks After FDA Rejects Key Cancer Drug Filing [Bloomberg]











5.2 PHARMA



Sanofi flashes more PhIII data on new multiple myeloma drug, setting up battle with Darzalex [EndPoints]











5.5.1 ASCO (GÉNÉRAL)



Preview of Noteworthy Abstracts from the ASCO20 Virtual Scientific Program [OBR]










5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS



Amgen Showcases Oncology Pipeline At ASCO 2020 [Amgen]











Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program [Bayer]











Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020 [Lilly]











AstraZeneca advances the science of cancer medicine with practice-changing data at the ASCO20 Virtual Scientific Program [AstraZeneca]











5.5.10 ASCO (HÉMATO)



J&J myeloma data heat up cell therapy battle [Biopharma Dive]











Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial [Merck]











5.5.13 ASCO (DIVERS)



Integrating Geriatric Assessment and Management Into Cancer Care Improves Quality of Life, Reduces Hospital Admissions for Older Patients [ASCO]











Quitting Smoking at Any Point, Even Close to a Lung Cancer Diagnosis, Improves Chances of Survival [ASCO]











5.5.16 ASCO (MÉDECINE DE PRÉCISION)



Amgen researchers confirm the lackluster data on the KRAS G12C drug AMG 510 reported at ESMO — but they still have a long way to go exploring options [EndPoints]










MacroGenics chief Scott Koenig details the upbeat cancer drug data from 2 programs that drove a big spike in their share price [EndPoints]











5.5.19 ASCO (REIN)



Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma [Merck]











5.5.2 ASCO (SEIN)



Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer [Merck]











5.5.3 ASCO (PROSTATE)



ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer [Fierce Pharma]











5.5.4.2 ASCO (IMMUNOTHÉRAPIES-COMBINAISONS)



Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types [Exelixis]











5.5.4.4 ASCO (IMMUNOTHÉRAPIES-POUMON)



New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC [Merck]











ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no [Fierce Pharma]











Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO [Roche]











In race to lead the TIGIT pack in I/O, Roche delivers positive PhII data — but questions linger [EndPoints]











Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy in Metastatic First-Line Non-Small Cell Lung Cancer Patients with PD-L1 ≥1% [BMS]











Bristol Myers Squibb spells out OS benefit of Opdivo/Yervoy combo plus 'limited' chemotherapy — is it enough to change practice? [EndPoints]











Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line Metastatic Non-Small Cell Lung Cancer in CheckMate -9LA Study [BMS]











5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)



Allogene gives first look at an 'off the shelf' cell therapy for lymphoma [Biopharma Dive]











Allogene spotlights their off-the-shelf CAR-T contender ‘501 with a snapshot on CRs and no GVHD [EndPoints]











Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20 [BMS]











5.5.7 ASCO (GYNÉCO)



Maintenance Therapy With PARP Inhibitor Olaparib Extends Survival By Over 1 Year in Patients With Relapsed Ovarian Cancer and BRCA Mutation [ASCO]











5.5.8 ASCO (POUMON)



ASCO: Roche's Alecensa stays on top of Xalkori with long-term survival showing [Fierce Pharma]











Days after rapid FDA approval, Lilly and Blueprint go head-to-head again at ASCO [EndPoints]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



COVID-19 in Children With Cancer in New York City [JAMA Oncology]